feedback from last night c/o cream23 Nov 2018 09:54
Non dilutive ...sounds good..please read on
Yes Freddie - I did see the ReNeuron presentation. While I don't know the ins and outs of the business , the tone was upbeat looking forward to PISCES III, which it is hoped will have placebo control group unlike PISCES I and II.
CTX Phase IIb (multi-centre trial in US) data expected early 2020.
Noted that Woodford has 35% stake and that they are gearing to a non-dilutive route using business development for funding.
Sorry - I didn't really get too much more than that, but as with VAL, the video should be available hopefully by Tuesday.